Aastrom sold 2.2M shares of 5.5 onver- tible preferred stock to institutional invest- ors; each preferred share converts into 1 common share; it will convert automatically 2 years after purchase if Aastrom¿s com- mon stock exceeds $10/share for 20 consec- utive trading days; Cowen & Co. acted as the placement agent in this all-or-none offering (11/97)
Allelix Biopharmaceuticals Inc. (Canada)
2
22.1
Allelix sold 2M shares at U.S.$11.03 each to Deutsche Morgan Grenfell Canada Ltd., which also acted as underwriter for the transaction (prices converted at an exchange rate of C$1.36/U.S.$1) (2/97)
Connetics Corp.
1.75
5.3
Connetics sold 1.75M shares of registered stock at $3.00/each to institutional inves- tors, including Amerindo Investment Ad- visors and existing investors; Connetics self-managed the offering (12/97)
ImClone Systems Inc.
3
23.6
ImClone sold 3M newly issued shares at $7.875 each to a select group of institutional and other investors, including Amerindo Investment Advisors Inc.; Spears, Benzak, Salomon & Farrell Inc. and Weiss, Peck & Greer LLC; Hambrecht & Quist LLC acted as financial advisor to ImClone; Genesis Mer- chant Group Securities LLC assisted Im- Clone in effecting the sale (3/97)
Neose Technologies Inc.
1.25
21.9
Neose sold 1.25M shares at $17.50 each to selected institutional investors; Vector Securities International Inc. acted as the placement agent (1/97)
Ribozyme Pharmaceuticals Inc.
1.4
11.2
Ribozyme sold 1.4M shares at $8.00/each to selected institutional investors; Nations- Banc Montgomery Securities Inc. acted as the placement agent in this best-efforts offering (10/97)
Shaman Pharmaceuticals Inc.
2
9
Shaman sold 2M shares at $4.50 each, prin- cipally to institutional investors; Hambrecht & Quist LLC acted as the placement agent (1/97)
Shaman Pharmaceuticals Inc.
1.6
8
Shaman registered 2M shares to sell to institutional investors in this self-managed offering, but ended up selling 1.6M shares at $4.97 each; new investors included T. Rowe Price Associates Inc. and Weiss, Peck & Greer LLC (4/97)
Transkaryotic Therapies Inc.
1.7
55.3
Transkaryotic Therapies sold 1.7M register- ed shares of common stock at $32.50 each to institutional investors (all of which were existing stockholders) in an oversubscribed offering; Pacific Growth Equities Inc. acted as the placement agent (7/97)
See subscription options